Durata Therapeutics Inc (DRTX.OQ)

DRTX.OQ on NASDAQ Stock Exchange Global Market

13.92USD
4:00pm EDT
Price Change (% chg)

$0.14 (+1.02%)
Prev Close
$13.78
Open
$13.97
Day's High
$14.36
Day's Low
$13.90
Volume
63,411
Avg. Vol
96,744
52-wk High
$18.14
52-wk Low
$8.16

DRTX.OQ

Chart for DRTX.OQ

About

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with... (more)

Overall

Beta: --
Market Cap (Mil.): $368.99
Shares Outstanding (Mil.): 26.78
Dividend: --
Yield (%): --

Financials

  DRTX.OQ Industry Sector
P/E (TTM): -- 146.41 33.29
EPS (TTM): -2.46 -- --
ROI: -75.29 -3.28 17.33
ROE: -194.03 -7.94 18.19
Search Stocks

U.S. FDA approves Durata's acute bacterial skin infection drug

WASHINGTON - The U.S. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc.

23 May 2014

UPDATE 1-U.S. FDA approves Durata's acute bacterial skin infection drug

WASHINGTON, May 23 - The U.S. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc.

23 May 2014

U.S. FDA approves Durata's acute bacterial skin infection drug

WASHINGTON, May 23 - The U.S. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc.

23 May 2014

Durata's anti-infective drug shows efficacy, safety: FDA panel

- Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U.S. Food and Drug Administration concluded on Monday.

31 Mar 2014

UPDATE 1-Durata's anti-infective drug shows efficacy, safety -FDA panel

March 31 - Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U.S. Food and Drug Administration concluded on Monday.

31 Mar 2014

Durata's anti-infective drug shows efficacy, safety -FDA panel

March 31 - Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U.S. Food and Drug Administration concluded on Monday.

31 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks